Study S000901

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06788626
Acronym: GALLOP2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: SINGLE
Status: NOT_YET_RECRUITING
Enrollment: 390
Start: 2025-02
Primary completion: 2028-02
Lead sponsor: Wei Hu
Conditions: Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment
Interventions: DRUG:Semaglutide 0.5 mg; OTHER:Standard medical treatment
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The ordinal shift of modified Rankin Scale [90±14 days after procedure]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0052933	ABSTRACT NUMBER: ESOC2026LT58 LT58 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN ACUTE LARGE VESSEL OCCLUSION STROKE TREATED BY REPERFUSION THERAPIES (GALLOP-2) – A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED END-POINT TRIAL Hao Wang, European Stroke Journal	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06788626